HCA Healthcare, Inc. $HCA Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 78.8% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,628 shares of the company’s stock after selling 6,054 shares during the period. Y Intercept Hong Kong Ltd’s holdings in HCA Healthcare were worth $694,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Mn Services Vermogensbeheer B.V. lifted its position in HCA Healthcare by 1.2% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 69,800 shares of the company’s stock worth $29,749,000 after buying an additional 800 shares during the period. UniSuper Management Pty Ltd increased its position in shares of HCA Healthcare by 4.9% during the third quarter. UniSuper Management Pty Ltd now owns 76,373 shares of the company’s stock worth $32,550,000 after acquiring an additional 3,537 shares during the last quarter. Facet Wealth Inc. lifted its position in shares of HCA Healthcare by 5.4% during the third quarter. Facet Wealth Inc. now owns 678 shares of the company’s stock worth $289,000 after purchasing an additional 35 shares during the last quarter. iA Global Asset Management Inc. grew its holdings in shares of HCA Healthcare by 12.9% during the third quarter. iA Global Asset Management Inc. now owns 45,064 shares of the company’s stock valued at $19,206,000 after purchasing an additional 5,136 shares during the last quarter. Finally, Strs Ohio boosted its holdings in HCA Healthcare by 14.2% during the third quarter. Strs Ohio now owns 90,280 shares of the company’s stock worth $38,477,000 after buying an additional 11,242 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

Shares of HCA opened at $496.30 on Tuesday. HCA Healthcare, Inc. has a one year low of $295.00 and a one year high of $527.55. The company has a market cap of $113.25 billion, a P/E ratio of 17.49, a P/E/G ratio of 1.50 and a beta of 1.36. The firm has a 50 day simple moving average of $480.98 and a two-hundred day simple moving average of $439.27.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings data on Tuesday, January 27th. The company reported $8.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.37 by $0.64. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The company had revenue of $19.51 billion during the quarter, compared to the consensus estimate of $19.67 billion. During the same quarter in the prior year, the firm posted $6.22 earnings per share. The firm’s revenue was up 6.7% compared to the same quarter last year. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 17th will be issued a dividend of $0.78 per share. This represents a $3.12 annualized dividend and a yield of 0.6%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio is currently 10.15%.

Insider Buying and Selling

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the firm’s stock in a transaction on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares of the company’s stock, valued at $1,652,105.73. This trade represents a 52.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their price target on HCA Healthcare from $500.00 to $558.00 and gave the company a “buy” rating in a research report on Wednesday, January 28th. Raymond James Financial set a $525.00 price objective on HCA Healthcare in a research report on Monday, October 27th. Robert W. Baird raised their target price on HCA Healthcare from $423.00 to $450.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. KeyCorp set a $503.00 price target on shares of HCA Healthcare in a research note on Wednesday, January 28th. Finally, Mizuho set a $540.00 price target on shares of HCA Healthcare in a report on Monday. Fifteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average target price of $519.71.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.